It is the first noninvasive eye drop therapy for AMD, and phase 2 clinical trial has recently been completed (safety and efficacy of ATG003 in patients with wet age-related macular degeneration (AMD), http://www.clinicaltrials.gov/ct2/show/NCT00414206?order=1) (safety and efficacy of ATG003 in patients with AMD receiving anti-VEGF, http://www.clinicaltrials.gov/ct2/show/NCT00607750). Here, VEGFA is linked to wet macular degeneration.